

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Jovan-Embiricos Morana</u> (Last) (First) (Middle) C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500 (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Allovir, Inc. [ALVR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 10/21/2021	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/21/2021		s ⁽¹⁾		85	D	\$24.75	1,399,647	I	By F2 MG Limited ⁽²⁾
Common Stock	10/21/2021		s ⁽¹⁾		15	D	\$24.75	346,996	I	By F2-TPO Investments, LLC ⁽³⁾
Common Stock	10/22/2021		s ⁽¹⁾		4,864	D	\$24.7697 ⁽⁴⁾	1,394,783	I	By F2 MG Limited ⁽²⁾
Common Stock	10/22/2021		s ⁽¹⁾		859	D	\$24.7697 ⁽⁴⁾	346,137	I	By F2-TPO Investments, LLC ⁽³⁾
Common Stock	10/25/2021		s ⁽¹⁾		6,604	D	\$24.8183 ⁽⁵⁾	1,388,179	I	By F2 MG Limited ⁽²⁾
Common Stock	10/25/2021		s ⁽¹⁾		1,165	D	\$24.8183 ⁽⁵⁾	344,972	I	By F2-TPO Investments, LLC ⁽³⁾
Common Stock								411,685	I	By F2 MC, LLC ⁽⁶⁾
Common Stock								2,800,000	I	By F2 Capital I 2020 LLC ⁽⁷⁾
Common Stock								13,420,970	I	By ElevateBio LLC ⁽⁸⁾
Common Stock								30,197	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

Explanation of Responses:

- These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.
- Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

